Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Friday, November 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the development of two pre-clinical short interfering RNA molecules aimed at targeting human HSD17beta13. This approach is intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a condition linked to chronic HBV infection. The research highlights the potential of these molecules in addressing metabolic disorders effectively.
Price reaction · baseline $7.1 (2025-11-06 close) · hit after-hours · 2 other ALGS headline(s) in the window, move may be shared
day 0 close
-0.4%
day 1
-3%
day 3
-9.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of two innovative RNA molecules.
  • Targeting a specific enzyme for metabolic disorders.
  • Potential to address a significant health issue.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What are the new RNA molecules targeting?

The new RNA molecules target human HSD17beta13.

What condition do these molecules aim to treat?

They aim to treat metabolic dysfunction-associated steatohepatitis (MASH).

Are the RNA molecules in clinical trials?

The RNA molecules are currently in pre-clinical development.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare HSD17beta13 metabolic dysfunction steatohepatitis RNA therapy
Last updated: Nov 7, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →